Linda C. Burkly, Ph.D., is a distinguished scientist and executive who currently serves as the Executive Vice President and Chief Scientific Officer at Editas Medicine, Inc. Dr. Burkly has been with Editas Medicine since 2015, where she has played a pivotal role in steering the company’s scientific strategy and advancing its mission to translate genome editing technologies into transformative medicines. Her leadership has been instrumental in guiding the company through the complex landscape of gene therapy and CRISPR technology, ensuring that Editas remains at the forefront of innovative medical solutions. Prior to joining Editas Medicine, Dr. Burkly amassed an impressive career in the biopharmaceutical industry. She held several key positions at Biogen, where she contributed significantly to the development of novel therapeutic approaches for various diseases. Her work at Biogen involved leading research teams and spearheading projects that resulted in several successful drug candidates. Dr. Burkly's academic credentials are equally robust; she earned her Ph.D. in Immunology from Harvard University and has authored numerous scientific publications that have advanced the field of molecular biology and genetics. In her current role at Editas Medicine, Dr. Burkly oversees the scientific direction of the company, including research and development efforts aimed at harnessing CRISPR/Cas9 and other genome editing technologies to treat a wide range of genetic disorders. Her strategic vision and deep understanding of the scientific challenges involved have been crucial in driving Editas’ pipeline forward. Under her leadership, the company has made significant strides in clinical trials and has continued to expand its portfolio of potential treatments, positioning Editas as a leader in the burgeoning field of genome editing.